Ticker Details
Coherus BioSciences, Inc. Coherus BioSciences Inc is a biotechnology company that develops biosimilar therapeutics. The company seeks to ensure successful drug development and manufacturing under very aggressive timelines.
IPO Date:	November 6, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$220.58M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.40 | 3.42%
Avg Daily Range (30 D):	$0.04 | 3.04%
Avg Daily Range (90 D):	$0.05 | 3.22%

Institutional Daily Volume
Avg Daily Volume:	1.15M
Avg Daily Volume (30 D):	.66M
Avg Daily Volume (90 D):	.95M

Trade Size
Avg Trade Size (Sh.):	161
Avg Trade Size (Sh.) (30 D):	173
Avg Trade Size (Sh.) (90 D):	206

Institutional Trades
Total Institutional Trades:	3,203
Avg Institutional Trade:	$1.5M
Avg Institutional Trade (30 D):	$1.7M
Avg Institutional Trade (90 D):	$1.49M
Avg Institutional Trade Volume:	.13M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.76M
Avg Closing Trade (30 D):	$1.7M
Avg Closing Trade (90 D):	$1.68M
Avg Closing Volume:	162.08K

News

Jul 22, 2026 @ 5:36 PM Coherus Oncology to Report Second Quarter 2026 Fin... Source: Na

Jun 23, 2026 @ 6:00 PM Coherus and Zumutor Biologics Announce Clinical Co... Source: Na

Feb 17, 2026 @ 9:11 PM Coherus Oncology, Inc. Announces Closing of Public... Source: Globe Newswire

Feb 13, 2026 @ 2:18 AM Coherus Oncology, Inc. Announces Pricing of Public... Source: Na

Nov 6, 2025 @ 6:54 PM Arvind Sood joins Coherus Oncology as Chief Strate... Source: Denny Lanfear

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$1.64	$-.28	$-.34
Diluted EPS	$1.64	$-.28	$-.34
Revenue	$46.88M	$12.31M	$12.75M
Gross Profit	$31.91M	$8.5M	$8.7M
Net Income / Loss	$186.27M	$-38.33M	$-37.64M
Operating Income / Loss	$-171.85M	$-36.15M	$-45.88M
Cost of Revenue	$14.98M	$3.81M	$4.05M
Net Cash Flow	$32.8M	$26.36M	$-14.47M
PE Ratio